MET and cancer: To this point, most of the successful attempts of ICI usage in cancers like liver cancer were demonstrated in combination or when pre-treated with small molecule tyrosine kinase inhibitors, suggesting the potential of cMET inhibitors when evolved in combination with ICIs in mUM patients (48, 49).